MaheshSwaminathanMD

Internal Medicine • Houston, TX

Hematology/Oncology

Assistant Professor

Join to view full profile

Dr. Swaminathan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Swaminathan's full profile

Already have an account?

Office
The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Houston, TX 77030

Education & Training

University at BuffaloFellowship, Hematology and Medical Oncology, 2019 - 2022
Carle Foundation HospitalResidency, Internal Medicine, 2014 - 2017
OtherClass of 2012

Certifications & Licensure

TX State Medical License 2017 - 2026
NY State Medical License 2019 - 2022
IL State Medical License 2014 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Effect of Digital Health Coaching on Self-Efficacy and Patient-Reported Outcomes in Individuals with Acute Myeloid and Chronic Lymphocytic Leukemia: A Pilot Randomized...
Jennifer Marvin-Peek, Valerie Shelton, Kelly Brassil, Bryan Fellman, Austin Barr
Acta Haematologica. 2024-06-11
3 citations
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Paul J Hampel, Mahesh Swaminathan, Kerry A Rogers, Erin M Parry, Jan A Burger
Blood Advances. 2024-05-28
2 citations
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2...
Alex Bataller, Guillermo Montalban-Bravo, Alexandre Bazinet, Yesid Alvarado, Kelly Chien
The Lancet. Haematology. 2024-03-01

Abstracts/Posters

Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome
Mahesh Swaminathan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Authored Content

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017